Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Add an action for EYEN.US, or sign in to see your action list.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael M. Rowe | Principal Financial Officer, CEO, President & Director | 1962 |
| Dr. Tsontcho Ianchulev M.D., M.P.H., MPH | Co-Founder & Executive Director | 1974 |
| Mr. Bren Kern | Chief Operating Officer | 1981 |
| Mr. Norbert Lowe | Senior Vice President of Commercial Operations | NA |
| Mr. Enrico Brambilla | Senior Vice President of R&D | NA |
| Alexander Lobo | Investor Contact | NA |
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.